Established as a market leader in premium restorative and cosmetic dental prosthetics, the lab operates a sophisticated digital-first production model. The company services an exceptionally loyal and defensive ledger of active prescribing dentists, strategically divided between high-value specialised Prosthodontists and high-volume General Practitioners (GPs).
Key Features & Investment Highlights:
High Pro Forma Profitability: FY2026 Normalised Adjusted profit stands at $603,158, showing continuous strength and growth trajectory from prior financial cycles.
State-of-the-Art Plant & Equipment: Fully automated facility boasting premium Roland dry/wet milling units, multiple Ivoclar porcelain and pressing furnaces, Asiga 3D printing equipment, and the full 3Shape design scanner suite.
Autonomous Team in Place: Staffed by a structured team.
Financials:
FY2026 Total Income (Revenue): $1,426,257
FY2026 Statutory EBITDA: $556,128
FY2026 Adjusted Pro Forma Profit: $603,158 (Reflecting immediate add-backs).
Stock Component: Inventory/Consumables to be transferred at settlement via standard Stock At Valuation (SAV).
Vendor Transition & Handover Support:
The current Director (acting as the Master Ceramist) is prepared to remain inside the business for an extended transition period of up to twelve (12) months under a mutually agreed, paid commercial consultancy or employment framework. During this extended period, the vendor is prepared to assist in training and upskilling current staff to support high quality outputs, facilitate clinical continuity, and aid customer retention metrics – de-risking the transition for the buyer.
Next Steps
Detailed 3-year comparative financial ledgers, product matrices, and the comprehensive Information Memorandum are strictly available to qualified buyers who have completed a formal Confidentiality Agreement (NDA) and verified financial capacity.
